de Guzman M Hannah Pu, Valencia Alejandro, Farinelli Adrian C
Sydney Eye Hospital, Sydney, New South Wales, Australia.
Clin Exp Ophthalmol. 2006 Mar;34(2):102-7. doi: 10.1111/j.1442-9071.2006.01170.x.
Glaucoma drainage devices are more commonly inserted into the anterior chamber because of the relative ease of this method of insertion. However, in certain cases, posterior placement of the tube may be necessary or may be more desirable. The outcome of a series of patients with glaucoma drainage devices inserted into the pars plana was examined.
Retrospective chart review of patients who underwent pars plana implantation of Molteno and Baerveldt glaucoma drainage devices at the Sydney Eye Hospital.
There were 33 cases reviewed. The mean follow-up period was 30.2 months. The mean final postoperative intraocular pressure was reduced to 13.4 +/- 4.4 mmHg (SD) from 33.06 +/- 8.47 mmHg preoperatively. The mean number of intraocular pressure-lowering medications in use postoperatively was 0.6 +/- 0.8, reduced from 3.6 +/- 1.27 medications in use preoperatively. Sixteen (48.5%) eyes were classified as complete successes, 14 (42.4%) eyes as qualified successes and three eyes (9%) as failures. Kaplan-Meier survival analysis for cumulative success (absence of failure) predicted 61.1% survival at 60 months. Complications included five cases of decompensation of corneas or corneal grafts, one case each of conjunctival wound dehiscence, large choroidal effusion, epiretinal membrane, Molteno plate extrusion and intraocular pressure unresponsive to medical therapy, and three cases of tube blockage.
In this series of patients, pars plana insertion of glaucoma drainage devices has been shown to be an effective alternative for selected cases where anterior chamber tube insertion is not possible or is not ideal.
由于青光眼引流装置植入前房的操作相对容易,所以该方法更为常用。然而,在某些情况下,可能需要将引流管置于后方或后方放置更为合适。我们对一系列将青光眼引流装置植入睫状体扁平部的患者的治疗结果进行了研究。
对在悉尼眼科医院接受Molteno和Baerveldt青光眼引流装置睫状体扁平部植入术的患者进行回顾性病历分析。
共纳入33例患者进行分析。平均随访时间为30.2个月。术后平均最终眼压从术前的33.06±8.47 mmHg降至13.4±4.4 mmHg(标准差)。术后使用的降眼压药物平均数量从术前的3.6±1.27种降至0.6±0.8种。16只眼(48.5%)被归类为完全成功,14只眼(42.4%)为合格成功,3只眼(9%)为失败。累积成功(无失败)的Kaplan-Meier生存分析预测60个月时的生存率为61.1%。并发症包括5例角膜或角膜移植失代偿、1例结膜伤口裂开、1例脉络膜大积液、1例视网膜前膜、1例Molteno板挤出和1例药物治疗无效的眼压升高,以及3例引流管堵塞。
在这组患者中,对于无法或不适合进行前房引流管植入的特定病例,睫状体扁平部植入青光眼引流装置已被证明是一种有效的替代方法。